Abstract
The duration of humoral immunity in patients treated with immunosuppressive drugs is poorly defined. The objective of the study was to investigate the effect of infliximab on the levels of antiviral antibodies against poliomyelitis, rubella and measles in rheumatoid arthritis (RA) patients. Fifty-two consecutive RA patients being treated with 3 mg/kg infliximab were prospectively studied. The antiviral antibody profiles for measles, rubella and three serotypes of poliomyelitis were tested on the day of the first infusion of infliximab and 6 months later. The study group comprised 36 women and 16 men (mean age 54 years, range 33–81) with a mean disease duration of 15 ± 9 years. Forty-two (81%) patients were being treated with methotrexate and 22 (42%) were receiving prednisone. All patients had baseline protective levels of antibodies against measles and the three strains of polio, while 48 (92%) patients had protective antibodies against rubella. No significant change in the levels of antiviral antibodies was observed after 6 months of treatment with infliximab: from 3.67 at baseline to 3.87 IU/ml for measles, 169.50–197.0 IU/ml for rubella. No change was noticed for the geometric mean concentrations of antibodies against strains of poliomyelitis: 366–478 IU/ml for the Mahoney polio strain, 906–845 IU/ml for the MEF strain and 175–196 IU/ml for the Sauket strain. Patients with longstanding RA conserve long-term immunity to common viruses despite the use of immunosuppressive drugs. Levels of antiviral antibodies against measles, rubella and polio remain stable under treatment with infliximab.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gluck T, Muller-Ladner U (2008) Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis 46(9):1459–1465. doi:10.1086/587063
Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357:1903–1915. doi:10.1056/NEJMoa066092
Arnett FC, Edworthy SM, Bloch DA (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324. doi:10.1002/art.1780310302
Ravikumar R, Anolik J, Looney J (2007) Vaccine response in patients with rheumatoid arthritis. Curr Rheumatol Rep 9:407–415. doi:10.1007/s11926-007-0065-3
Salliot C, Dougados M, Gossec L (2008) Risk of serious infection during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analysis of randomized placebo-controlled trials. Ann Rheum Dis (Jan):18
Reinhardt D, Houliara K, Pekrun A, Lakomek M, Krone B (2003) Impact of conventional chemotherapy on levels of antibodies against vaccine-preventable diseases in children treated for cancer. Scand J Infect Dis 35(11–12):851–877. doi:10.1080/00365540310016600
Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D et al (2006) Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF-alpha blockers. Ann Rheum Dis 65:191–194. doi:10.1136/ard.2005.036434
Kubota T, Nii T, Nanki T, Kohsaka H, Harigai M, Komano Y et al (2007) Anti-tumor necrosis factor does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol 17(6):531–533. doi:10.1007/s10165-007-0632-5
Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, RimmelzwaanGF, Kroon FP (2008) The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 67(5):713–716
Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB (2004) The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 33:283–288. doi:10.1053/j.semarthrit.2003.10.003
Kapetanovic MC, Saxne T, Sjoholm A et al (2006) Influence of methotrexate, TNF blockers, and prednisone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology 45:106–111
O’Dell J, Gilg J, Palmer W, Truedsson L, Jönsson G, Geborek P (1996) Pneumococcal vaccine in rheumatoid arthritis: decreased response while taking methotrexate. J Clin Rheumatol 2:59–63
Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL (2005) Responses to the pneumococcal vaccine in patients with early rheumatoid arthritis. Ann Rheum Dis 64(Suppl III):422
Kaine J, Kivitz A, Birbara C, Luo AY (2007) Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 34(2):272–279
Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC (2006) Circulating level of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54(3):723–732. doi:10.1002/art.21650
Acknowledgments
The study was supported by internal institutional funds.
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kaufman, I., Moscovici, Y.B., Abudi, Y. et al. The effect of infliximab on antiviral antibody profiles in patients with rheumatoid arthritis. Rheumatol Int 30, 325–329 (2010). https://doi.org/10.1007/s00296-009-0959-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-0959-7